Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 2/20 | 0.43 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.43 |
| ▸ | MMP1 | P03956 | 2/20 | 0.32 |
| ▸ | MMP13 | P45452 | 2/20 | 0.32 |
| ▸ | RORC | P51449 | 6/20 | 0.32 |
| ▸ | RORA | P35398 | 2/20 | 0.31 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.31 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.31 |
| ▸ | RORB | Q92753 | 2/20 | 0.31 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.30 |
| ▸ | MMP2 | P08253 | 1/20 | 0.30 |
| ▸ | MMP9 | P14780 | 1/20 | 0.30 |
| ▸ | GCGR | P47871 | 1/20 | 0.30 |
| ▸ | GIPR | P48546 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5999984 | 0.94 | PTPN1 (0.50) | PTPN1PTPN2MMP1MMP13RORC | |
| SCHEMBL5999198 | 0.90 | PTPN1 (0.42) | PTPN1PTPN2MMP1MMP13S1PR1 | |
| SCHEMBL6000861 | 0.89 | PTPN1 (0.52) | PTPN1PTPN2MMP1MMP13S1PR1 | |
| SCHEMBL6000921 | 0.80 | PTPN2 (0.68) | PTPN1PTPN2MMP1MMP13MMP2 | |
| SCHEMBL6000635 | 0.79 | PTPN1 (0.49) | PTPN1PTPN2MMP1MMP13MMP2 | |
| SCHEMBL6000684 | 0.79 | TDP1 (0.41) | PTPN1MMP1RORCRORANR1H2 | |
| SCHEMBL6000561 | 0.79 | PTPN1 (0.36) | PTPN1PTPN2RORCRORANR1H2 | |
| SCHEMBL5999157 | 0.78 | PTPN1 (0.52) | PTPN1PTPN2S1PR1 | |
| SCHEMBL5999379 | 0.76 | PTPN1 (0.43) | PTPN1PTPN2 | |
| SCHEMBL6000680 | 0.75 | PTPN1 (0.44) | PTPN1PTPN2MMP1MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060122181-A1 | Heteroaromatic pentacyclic compound and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2006-06-08 | — | — | US | claimed |
| EP-1553091-A1 | HETEROAROMATIC PENTACYCLIC COMPOUND AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2005-07-13 | — | — | EP | claimed |
| US-20060122181-A1 | Heteroaromatic pentacyclic compound and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2006-06-08 | — | — | US | disclosed |
| EP-1553091-A1 | HETEROAROMATIC PENTACYCLIC COMPOUND AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2005-07-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122181-A1 | Heteroaromatic pentacyclic compound and medicinal use thereof | PTPN11, PTPN1, PTPN3 | PTPN1 2/4885PTPN2 11/4885MMP1 3740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.